SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-005168
Filing Date
2022-01-19
Accepted
2022-01-19 08:00:33
Documents
14
Period of Report
2022-01-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm223236d1_8k.htm   iXBRL 8-K 28087
2 EXHIBIT 99.1 tm223236d1_ex99-1.htm EX-99.1 19891
6 GRAPHIC tm223236d1_ex99-1img001.jpg GRAPHIC 21173
  Complete submission text file 0001104659-22-005168.txt   260330

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vyne-20220119.xsd EX-101.SCH 3060
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20220119_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20220119_pre.xml EX-101.PRE 22613
8 EXTRACTED XBRL INSTANCE DOCUMENT tm223236d1_8k_htm.xml XML 3708
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 22536813
SIC: 2834 Pharmaceutical Preparations